Pre-made Efalizumab benchmark antibody ( Whole mAb, anti-ITGAL therapeutic antibody, Anti-CD11A/LFA-1/LFA1A Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-166

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-166 Category Tag

Product Details

Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -mab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a[1] subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.

Products Name (INN Index)

Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody

INN Name

Efalizumab

Target

ITGAL

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

NFD

100% SI Structure

3eo9:HL/3eoa:HL:BA/3eob:HL:BA

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2001

Companies

Genentech,Merck Serono,XOMA

Conditions Approved

Psoriasis

Conditions Active

NA

Conditions Discontinued

Psoriatic arthritis,Type 1 diabetes mellitus

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

ITGAL

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide